The top ten best-selling cancer drugs of 2013
According to industry data, in 2013 the world's best-selling cancer drug is MabThera (rituximab / MabThera, Genentech / Roche), for the treatment of blood malignancies, with sales of $ 8 billion. This figure is only associated with cancer treatment-related sales, not included in other indications or sales purposes. For example, sales of rituximab in the treatment of rheumatoid arthritis are not included.
The five best-selling in the United States are consensus with the world wild ranking. According to additional data, in 2013 the United States' best-selling cancer drug is also rituximab, on sales of $ 3.59 billion. Followed by bevacizumab, with sales of $ 2.78 billion, lenalidomide , $ 2.49 billion, imatinib, $ 1.94 billion, trastuzumab, $ 1.93 billion.
Quickly compare these two sets of figures show that U.S. sales account for a large proportion of global sales.
Best-selling cancer drug in the list will certainly continue to change in the next few years because several best-selling drugs facing patent expiration and the emergence of competitions.
Recently, in a research paper published in ‘Nature', researchers from Harvard Medical School, Japan RIKEN and other countries conducted a global large-scale study to reveal the genetic basis of rheumatoid arthritis (RA). This provides foundation and ideas for the development of new drugs to treat rheumatoid arthritis.
Genome-wide association study is a research tool for the identification of genes lead to human disease. RA is an autoimmune disease in which the body's defense system responds to a "false alarm" and attacks the joints. Nowadays, the researchers have found that many genes have a close relationship with RA.
In this latest study, the researchers performed a genome-wide association study meta-analysis in a total of over 100,000 subjects of European and Asian ancestries (29,880 RA cases and 73,758 controls), by evaluating ~10 million single-nucleotide polymorphisms (SNPs).Ultimately, they identified 42 novel RA risk loci at a genome-wide level, making the total risk loci to 101.
Through bioinformatics analysis, researchers discriminate 98 genes- that can lead to arthritis-out of the 101 regions. This provides some ideas for further development of the new targeted drugs for RA. By the way, although there are no effective drugs to treat RA currently, but the researchers said that the anti-cancer drugs could also treat RA or other diseases, such as CDK4 /6 inhibitor.
Finally, the researchers said that the study not only revealed the fundamental genes, pathways and cell types that contribute to RA pathogenesis, but also provides a lot of research data, but also provide important information for the later development of new targeted drugs.
The researchers built a synthetic adhesin with an antibody that binds to green fluorescent protein (GFP). They incorporated the new adhesin's gene into the chromosome of E. coli, along with a gene for a bioluminescent protein. The bacteria's targets were human cancer cells that the researchers modified to express GFP on their surfaces. After mixing the human and bacterial cells together, the team inspected the cells with fluorescence imaging and found that the bacteria colonized the cancer cells. Bacteria without the synthetic adhesin did not adhere to the human cells.
The five best-selling in the United States are consensus with the world wild ranking. According to additional data, in 2013 the United States' best-selling cancer drug is also rituximab, on sales of $ 3.59 billion. Followed by bevacizumab, with sales of $ 2.78 billion, lenalidomide , $ 2.49 billion, imatinib, $ 1.94 billion, trastuzumab, $ 1.93 billion.
Quickly compare these two sets of figures show that U.S. sales account for a large proportion of global sales.
Best-selling cancer drug in the list will certainly continue to change in the next few years because several best-selling drugs facing patent expiration and the emergence of competitions.
Recently, in a research paper published in ‘Nature', researchers from Harvard Medical School, Japan RIKEN and other countries conducted a global large-scale study to reveal the genetic basis of rheumatoid arthritis (RA). This provides foundation and ideas for the development of new drugs to treat rheumatoid arthritis.
Genome-wide association study is a research tool for the identification of genes lead to human disease. RA is an autoimmune disease in which the body's defense system responds to a "false alarm" and attacks the joints. Nowadays, the researchers have found that many genes have a close relationship with RA.
In this latest study, the researchers performed a genome-wide association study meta-analysis in a total of over 100,000 subjects of European and Asian ancestries (29,880 RA cases and 73,758 controls), by evaluating ~10 million single-nucleotide polymorphisms (SNPs).Ultimately, they identified 42 novel RA risk loci at a genome-wide level, making the total risk loci to 101.
Through bioinformatics analysis, researchers discriminate 98 genes- that can lead to arthritis-out of the 101 regions. This provides some ideas for further development of the new targeted drugs for RA. By the way, although there are no effective drugs to treat RA currently, but the researchers said that the anti-cancer drugs could also treat RA or other diseases, such as CDK4 /6 inhibitor.
Finally, the researchers said that the study not only revealed the fundamental genes, pathways and cell types that contribute to RA pathogenesis, but also provides a lot of research data, but also provide important information for the later development of new targeted drugs.
The researchers built a synthetic adhesin with an antibody that binds to green fluorescent protein (GFP). They incorporated the new adhesin's gene into the chromosome of E. coli, along with a gene for a bioluminescent protein. The bacteria's targets were human cancer cells that the researchers modified to express GFP on their surfaces. After mixing the human and bacterial cells together, the team inspected the cells with fluorescence imaging and found that the bacteria colonized the cancer cells. Bacteria without the synthetic adhesin did not adhere to the human cells.
Source...